# Daiichi Sankyo

Delivery platforms — Vector engineering.

Source: https://en.bioecon.ru/companies/daiichi-sankyo/
Updated: 2026-07-02

- Country: Japan

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | 2,123.0 billion JPY for FY2025 | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/materials/2025/202601_JPM%20Conference_slide.pdf, https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Reference_Data_E.pdf |
| Headcount | 20,171 employees globally (as of March 31, 2026) | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2024/1.%20About%20Daiichi%20Sankyo.pdf |
| Production site | 13 production sites globally | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2024/1.%20About%20Daiichi%20Sankyo.pdf |
| Funding | Approximately 300 billion JPY ($1.9 billion) committed to global ADC manufacturing expansions as of early 2026 | https://www.fiercepharma.com/manufacturing/daiichi-sankyo-tallies-19b-enhertu-manufacturing-investments-across-globe-report, https://www.pharmamanufacturing.com/facilities/article/55341804/daiichi-sankyo-invests-19b-to-boost-adc-production-globally |
| Capacity | Biologics manufacturing platforms utilize CHO cell gene expression systems demonstrating up to 10g/L productivity [medium confidence] | https://www.daiichisankyo.com/files/investors/library/materials/2023/DS%20seminar%202023_E.pdf |

Independent sources: fiercepharma.com, pharmamanufacturing.com

## Technologies

- [Antibody-drug conjugates (ADCs)](https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/)